1. Home
  2. MLCO vs RCUS Comparison

MLCO vs RCUS Comparison

Compare MLCO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Melco Resorts & Entertainment Limited

MLCO

Melco Resorts & Entertainment Limited

HOLD

Current Price

$8.85

Market Cap

3.2B

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$25.82

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLCO
RCUS
Founded
2004
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
MLCO
RCUS
Price
$8.85
$25.82
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$10.08
$28.88
AVG Volume (30 Days)
1.8M
1.7M
Earning Date
11-06-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$5,061,044,000.00
$240,000,000.00
Revenue This Year
$13.64
N/A
Revenue Next Year
$3.57
N/A
P/E Ratio
$34.27
N/A
Revenue Growth
11.46
N/A
52 Week Low
$4.55
$6.50
52 Week High
$10.15
$26.40

Technical Indicators

Market Signals
Indicator
MLCO
RCUS
Relative Strength Index (RSI) 50.05 76.50
Support Level $8.74 $24.32
Resistance Level $9.53 $26.40
Average True Range (ATR) 0.34 1.29
MACD -0.03 0.08
Stochastic Oscillator 37.74 89.51

Price Performance

Historical Comparison
MLCO
RCUS

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: